產(chǎn)品訂購信息：
英文名稱  Anti-RelB 

中文名稱   轉(zhuǎn)錄因子RelB蛋白抗體費用 

別    名  I REL; IREL; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; RelB; Reticuloendotheliosis viral oncogene homolog B; Transcription factor RelB; v rel avian reticuloendotheliosis viral oncogene homolog; v rel reticuloendotheliosis viral oncogene homolog B; RELB_HUMAN; I-Rel.

濃    度   1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog, Pig, Cow, Horse 

產(chǎn)品類型   一抗  

研究領(lǐng)域     免疫學(xué) 信號轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子

蛋白分子量  predicted molecular weight: 64kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human RelB 

亞    型   IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

轉(zhuǎn)錄因子RelB蛋白抗體費用 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 The NFKB complex consists of NFKB1 or NFKB2 bound to REL, RELA, or RELB. The NFKB complex is inhibited by I kappa B proteins (NFKBIA, or NFKBIB), which inactivate NF kappa B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I kappa B proteins by kinases (IKBKA, or IKBKB,) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF kappa B complex.

Function : NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment.

Subunit : Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and NFKB2/p100. Interacts with NFKBID.

Subcellular Location : Nucleus. Cytoplasm, cytoskeleton, centrosome. Note=Co-localizes with NEK6 in the centrosome.

Post-translational modifications : Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.

Similarity : Contains 1 RHD (Rel-like) domain.

Database links : UniProtKB/Swiss-Prot: Q01201.2

NOS-2 peptide 合成酶-2多肽抗原Multi-class antibodies規(guī)格： 0.5mg

Anti-AQP2 水通道蛋白-2抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh phospho-ATG7(Ser95) 磷酸化自噬相關(guān)蛋白7抗體 規(guī)格 0.1ml

山羊抗人 IgM/HRP 0.1ml 美國Jackson公司分裝

Viperin 英文名稱： 病毒抑制蛋白Viperin抗體 0.2ml

Dio3 英文名稱： 甲狀腺素5'脫酶3抗體 0.1ml

Anti-AQP2 水通道蛋白-2抗體Multi-class antibodies規(guī)格： 0.1ml

Anti-IL-16/FITC 熒光素標(biāo)記白介素16抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rabbit Anti-human sIgA/FITC 熒光素標(biāo)記兔抗人分泌型IgA抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Apg12 自噬相關(guān)蛋白12抗體 規(guī)格 0.2ml

Rabbit Anti-rat IgG/RBITC 羅丹明標(biāo)記的兔抗大鼠IgG 0.3ml

GIMAP6 英文名稱： GTP酶IMAP家族成員6抗體 0.2ml

Rhesus antibody Rh Rabbit Anti-human sIgA/Alexa Fluor 350 Alexa Fluor 350標(biāo)記的兔抗人分泌型IgA 規(guī)格 0.1ml

Rabbit Anti-human sIgA/FITC 熒光素標(biāo)記兔抗人分泌型IgA抗體Multi-class antibodies規(guī)格： 0.2ml

SIRT3 英文名稱： 線粒體乙?；?抗體 0.2ml

EphB2 英文名稱： 酪酸蛋白激酶受體B2抗體 0.1ml

Caspase 激活的脫氧核糖核酸酶抗體 Anti-CAD/CPAN 0.1ml

Anti-Phospho-Tuberin/TSC2 (Tyr1571)/FITC 熒光素標(biāo)記磷酸化馬鈴薯球蛋白(性硬化)抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Phospho-HSP27(Ser78) 磷酸化熱休克蛋白27抗體 規(guī)格 0.1ml

cath-B/CB(Cathepsin B) 組織蛋白酶B抗原Multi-class antibodies規(guī)格： 0.5mg

正常細(xì)胞

CAM191 EBV-轉(zhuǎn)化人淋巴細(xì)胞

CD4 Others Human 人 CD4 / LEU3 (aa 1-208) 人細(xì)胞裂解液 (陽性對照)

CL-0094HCC827(人非小細(xì)胞細(xì)胞)5×106cells/瓶×2

人少突膠質(zhì)前體細(xì)胞-懸浮生長裂解物HOPC-os L

人原胚腎轉(zhuǎn)化細(xì)胞;293 Ad5 人臍內(nèi)皮細(xì)胞完全培養(yǎng)基 100mL

CL-0106HFL1(人)5×106cells/瓶×2

KIR2DL4 Others Human 人 KIR2DL4 / CD158D CHO細(xì)胞裂解液 (陽性對照)

人表皮黑色素細(xì)胞-淺色素裂解物HELM-l L

新生牛眼晶體上皮細(xì)胞;NBLE 人細(xì)胞，SW579細(xì)胞 RIN-m5F細(xì)胞，小鼠β瘤細(xì)胞

人膀胱上皮永生化細(xì)胞;SV-HUC-1

EPHA4 Others Human 人 EPHA4 人細(xì)胞裂解液 (陽性對照)

轉(zhuǎn)錄因子RelB蛋白抗體費用 正常細(xì)胞

CAM191 EBV-轉(zhuǎn)化人淋巴細(xì)胞

CD4 Others Human 人 CD4 / LEU3 (aa 1-208) 人細(xì)胞裂解液 (陽性對照)

CL-0094HCC827(人非小細(xì)胞細(xì)胞)5×106cells/瓶×2

人少突膠質(zhì)前體細(xì)胞-懸浮生長裂解物HOPC-os L

人原胚腎轉(zhuǎn)化細(xì)胞;293 Ad5 人臍內(nèi)皮細(xì)胞完全培養(yǎng)基 100mL

抗體的生物素化標(biāo)記實驗要點：

1. 轉(zhuǎn)錄因子RelB蛋白抗體費用 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；

8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）轉(zhuǎn)錄因子RelB蛋白抗體費用 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力。抗體的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。